| Revenue growth | +24.3% YoY to INR 28,205 Mn |
|---|---|
| Margins | EBITDA margin +103 bps YoY; gross margin -131 bps YoY |
| Order book | ARV 'strong orderbook' cited; no value disclosed |
| Demand visibility | Canada 50+ product pipeline; Europe base business plus launches |
| Management confidence | Qualitative only: 'expect continued growth' for domestic |
Growth
International +34.5% (RoW +41.1%, Europe +36.0%, Canada +24.0%); Domestic +12.0%. EBITDA +30.9%, PAT +29.3%.
Outlook
No numeric guidance. Management expects continued domestic growth over the full year; Lenacapavir filing and 50+ Canada pipeline cited.
Risks
Gross margin fell 131 bps YoY to 59.5%. Net debt rose to INR 13,171 Mn (0.6x TTM EBITDA) on Mantra and Gennova payments.
Last quarter's promises, checked
Delivered
- Guided FY27 EBITDA +70-100bps → Q2 +103bps YoY (= BEAT)
- Guided FY27 gross margin 59-60% → Q2 59.5% (= BEAT)
- Guided Q2-end net debt ~INR 1,450 Cr → Q2 INR 1,317 Cr (= BEAT)
Partly delivered
- Guided FY27 low-to-mid-teens revenue growth → Q2 +24.3% YoY, quarter only, FY not reported (= PARTIAL)
- Guided Q2 domestic in line with IPM → domestic +12.0%, IPM not disclosed (= PARTIAL)
Missed
- Guided Q2 Quebec semaglutide launch via Reddy's → not in Q2 launches; timing deferred on call (= MISS)
Investor Presentation filed with BSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,160.40
- Market cap
- ₹40,985 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 37.5×Sector 37.9×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue ₹2,820 Cr (+24%) and PAT ₹325 Cr (+29%) were strong. FY27 revenue growth guidance raised to above 20%. Net debt rose ₹263 Cr on acquisition payouts. FY28 guidance withheld.
- Call
- Guides 20% growth
Emcure Pharmaceuticals Q2 FY27 Results: Net Profit ₹325.1 Cr, Up 29.3% YoY
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,820 Cr (+24.3% YoY) and net profit of ₹325.1 Cr (+29.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹325.1 Cr · +29.3% YoY
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Emcure Pharmaceuticals Legal & Regulatory
Emcure Pharmaceuticals received Income-tax Department orders imposing aggregate penalties of Rs. 57.74 Crore for assessment years 2015-16 to 2021-22. The company is evaluating legal remedies.
- Value
- ₹57.74 Cr